AG, W., E, S., T, L., M, L., E, K., M, D., . . . GI, S. (2026). Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(19), 4250. https://doi.org/10.1158/1078-0432.CCR-26-0721
Παραπομπή σε μορφή Chicago (17η εκδ.)AG, Waks, et al. "Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 32, no. 19 (2026): 4250. https://doi.org/10.1158/1078-0432.CCR-26-0721.
Παραπομπή σε μορφή MLA (9th εκδ.)AG, Waks, et al. "Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 32, no. 19, 2026, p. 4250, https://doi.org/10.1158/1078-0432.CCR-26-0721.